Interleukin-19 impairment in active Crohn's disease patients.
about
Toll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activityInsights from GWAS: emerging landscape of mechanisms underlying complex trait diseaseAltered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells.TFF2 deficiency exacerbates weight loss and alters immune cell and cytokine profiles in DSS colitis, and this cannot be rescued by wild-type bone marrow.The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models.The Interleukin-20 Cytokines in Intestinal Diseases.
P2860
Interleukin-19 impairment in active Crohn's disease patients.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Interleukin-19 impairment in active Crohn's disease patients.
@ast
Interleukin-19 impairment in active Crohn's disease patients.
@en
type
label
Interleukin-19 impairment in active Crohn's disease patients.
@ast
Interleukin-19 impairment in active Crohn's disease patients.
@en
prefLabel
Interleukin-19 impairment in active Crohn's disease patients.
@ast
Interleukin-19 impairment in active Crohn's disease patients.
@en
P2093
P2860
P50
P1433
P1476
Interleukin-19 impairment in active Crohn's disease patients.
@en
P2093
Carlos Zamora-Atenza
Cándido Juárez
Elena Serrano
Elisabet Cantó
Esther Garcia Planella
Jordi Gordillo
Juan Camilo Nieto
Ma Angels Ortiz
Orlando García-Bosch
P2860
P304
P356
10.1371/JOURNAL.PONE.0093910
P407
P577
2014-04-09T00:00:00Z